CD4 and Hodgkins lymphoma: Although the potential role of CD4+ T cells as inflammatory/immune regulators in HL has previously been associated with response (26, 27), we found no changes in effector or regulatory CD4+ T cells except CD4+ TEMRA and NK cells differentially prevalent at baseline across treatment groups.